global glp-1 market size 2025 Receptor Agonist Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 GLP-1 Agonists Weight Loss Drugs

6 Benefits of Combining Insulin and GLP-1 Drugs Key takeaways: Basal insulin and GLP-1 combinations like Xultophy and Soliqua help lower A1C with less risk of hypoglycemia

Age-related sarcopenia begins around age 35 and accelerates during perimenopause and menopause, primarily due to declining estrogen levels

One theory, he said, is that because the medications suppress appetite, some patients may not get enough key nutrients, such as vitamin D and calcium, which are important for maintaining bone health

The association between GLP-1 RA initiation and first-time diagnoses may suggest that healthcare providers are actively screening for conditions like T2D and sleep apnea following the prescription

Cell 185(14):2478-2494.e28 Zheng Z, Zong Y, Ma Y, Tian Y (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy